An Investigation of the Effects of Riluzole in Patients With Post-Traumatic Stress Disorder (PTSD)
Status: Active, no longer recruiting
Phase of Trial: Phase I
Latest Information Update: 26 Sep 2019
Price : $35 *
At a glance
- Drugs Riluzole (Primary)
- Indications Post-traumatic stress disorders
- Focus Therapeutic Use
- 23 Sep 2019 Status changed from recruiting to active, no longer recruiting.
- 22 Aug 2018 Planned End Date changed from 1 Dec 2018 to 1 Dec 2019.
- 22 Aug 2018 Planned primary completion date changed from 1 Dec 2018 to 1 Dec 2019.